This week, Peter Simons covers an article in JAMA by FDA advisory committee members that reveals ethical issues with the FDA's collaboration with pharmaceutical company Biogen to re-analyze their two failed trials of Alzheimer's disease drug aducanumab. He also covers a study that found that viewing mental health as a continuum reduces stigma.

• Ethical Issues Raised Over FDA Collaboration with Biogen on Failed Drug
• Viewing Mental Differences on a Continuum Reduces Stigma

Visit madinamerica.com for more news, articles and research updates.